Health Care·Biotechnology·$24.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $6.39 | N/A | +3.77% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $6.39 | N/A | +3.77% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting ongoing efforts to enhance shareholder value. However, they did not provide detailed guidance for the upcoming quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering value to our stakeholders.
United Therapeutics reported a positive surprise in EPS, which contributed to a 2.44% increase in stock price following the announcement. The lack of revenue data and guidance may leave investors cautious, but the EPS beat indicates strong performance in profitability. Overall, the results suggest a stable outlook for the company, at least in terms of earnings.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WELLTOWER INC REIT
Oct 28, 2024